Kura Oncology shares tumbled 40% in premarket trading

Tiger Newspress2021-11-24

Kura Oncology shares tumbled 40% in premarket trading.The FDA has slapped a clinical hold on the early-stage program for one of Kura’s cancer drugs following a patient’s death in a clinical trial.

The biotech $KURA reported early Wednesday that the Phase Ib study of KO-539 for acute myeloid leukemia would be halted, suspending enrollment, while researchers and the FDA probed the death. Patients already on the drug can continue taking it.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

  • Investoro
    2021-11-24
    Investoro
    Oh my
  • Desmondong
    2021-11-24
    Desmondong
    😡
  • QueenAlice
    2021-11-24
    QueenAlice
    That's really sad to hear :(
  • Bull_Lion
    2021-11-24
    Bull_Lion
    The perils of investing in Pharma especially early stage companies
    • Mattsailor
      High risk , high returns or loss. It's very difficult to predict. Sometimes it's like a shot in the dark.
    • Bull_Lion
      And not to mention unknown
  • Jfierydragon
    2021-11-24
    Jfierydragon
    Like n commet
  • TradeMore
    2021-11-24
    TradeMore
    Ok
发表看法
16